Revenues

Product Revenues

Revenues by product are summarized as follows:



	For the Three Months Ended September 30,
(In millions)	2018						2017
	United States		Rest of World		Total		United States		Rest of World		Total
Multiple Sclerosis:
TECFIDERA	$	842.1	$	247.9	$	1,090.0	$	836.3	$	233.3	$	1,069.6
Interferon*	421.5		168.6		590.1		473.3		188.7		662.0
TYSABRI	253.0		217.2		470.2		266.8		202.6		469.4
FAMPYRA	—		22.5		22.5		—		24.3		24.3
ZINBRYTA	—		—		—		—		14.2		14.2
Spinal Muscular Atrophy:
SPINRAZA	223.9		243.8		467.7		197.6		73.3		270.9
Other Product Revenues:
FUMADERM	—		4.8		4.8		—		10.7		10.7
BENEPALI	—		123.4		123.4		—		99.2		99.2
FLIXABI	—		11.4		11.4		—		2.2		2.2
Total product revenues	$	1,740.5	$	1,039.6	$	2,780.1	$	1,774.0	$	848.5	$	2,622.5

*Interferon includes AVONEX and PLEGRIDY.



	For the Nine Months Ended September 30,
(In millions)	2018						2017
	United States		Rest of World		Total		United States		Rest of World		Total
Multiple Sclerosis:
TECFIDERA	$	2,396.8	$	766.9	$	3,163.7	$	2,462.4	$	676.0	$	3,138.4
Interferon*	1,237.5		528.4		1,765.9		1,439.8		561.1		2,000.9
TYSABRI	768.2		631.3		1,399.5		861.7		648.7		1,510.4
FAMPYRA	—		69.9		69.9		—		67.4		67.4
ZINBRYTA	—		1.4		1.4		—		41.0		41.0
Spinal Muscular Atrophy:
SPINRAZA	617.8		636.5		1,254.3		438.8		82.4		521.2
Hemophilia:
ELOCTATE	—		—		—		42.2		6.2		48.4
ALPROLIX	—		—		—		21.0		5.0		26.0
Other Product Revenues:
FUMADERM	—		17.3		17.3		—		30.7		30.7
BENEPALI	—		359.9		359.9		—		253.2		253.2
FLIXABI	—		29.2		29.2		—		4.7		4.7
Total product revenues	$	5,020.3	$	3,040.8	$	8,061.1	$	5,265.9	$	2,376.4	$	7,642.3

*Interferon includes AVONEX and PLEGRIDY.

We recognized revenues from two wholesalers accounting for 30.7% and 19.3% of gross product revenues for the three months ended September 30, 2018, and 32.4% and 18.0% of gross product revenues for the nine months ended September 30, 2018.

We recognized revenues from two wholesalers accounting for 33.7% and 20.8% of gross product revenues for the three months ended September 30, 2017, and 34.9% and 21.0% of gross product revenues for the nine months ended September 30, 2017.

An analysis of the change in reserves for discounts and allowances is summarized as follows:



(In millions)	Discounts			Contractual Adjustments			Returns			Total
Balance, as of December 31, 2017	$	109.6		$	606.0		$	46.0		$	761.6
Current provisions relating to sales in current year	498.9			1,949.6			18.0			2,466.5
Adjustments relating to prior years	(0.3		)	(7.0		)	0.1			(7.2		)
Payments/credits relating to sales in current year	(373.7		)	(1,285.8		)	(0.8		)	(1,660.3		)
Payments/credits relating to sales in prior years	(107.8		)	(495.2		)	(21.8		)	(624.8		)
Balance, as of September 30, 2018	$	126.7		$	767.6		$	41.5		$	935.8

The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:



(In millions)	As of September 30, 2018		As of December 31, 2017
Reduction of accounts receivable	$	177.3	$	189.6
Component of accrued expenses and other	758.5		572.0
Total reserves	$	935.8	$	761.6

Revenues from Anti-CD20 Therapeutic Programs

Revenues from anti-CD20 therapeutic programs are summarized as follows:



	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
(In millions)	2018		2017		2018		2017
Biogen’s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA	$	358.0	$	325.1	$	1,066.6	$	996.1
Other revenues from anti-CD20 therapeutic programs	153.7		81.4		378.7		148.1
Total revenues from anti-CD20 therapeutic programs	$	511.7	$	406.5	$	1,445.3	$	1,144.2

For additional information on our relationship with Genentech, please read Note 20, Collaborative and Other Relationships, to our consolidated financial statements included in our 2017 Form 10-K.

Other Revenues

Other revenues are summarized as follows:



	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
(In millions)	2018			2017			2018			2017
Revenues from collaborative and other relationships:
AbbVie	$	(0.7	)	$	(2.8	)	$	(7.9	)	$	(12.6	)
Samsung Bioepis and other	48.1			9.0			80.7			34.1
Other royalty and corporate revenues:
Royalty	7.9			11.8			35.8			49.1
Other corporate	91.9			30.8			311.6			109.8
Total other revenues	$	147.2		$	48.8		$	420.2		$	180.4

For additional information on our collaboration arrangements with AbbVie and Samsung Bioepis, please read Note 17, Collaborative and Other Relationships, to these condensed consolidated financial statements.